vs
Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Organon & Co. (OGN). Click either name above to swap in a different company.
Organon & Co. is the larger business by last-quarter revenue ($1.5B vs $749.2M, roughly 1.9× CLOVER HEALTH INVESTMENTS, CORP.). Organon & Co. runs the higher net margin — 10.0% vs 3.6%, a 6.4% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (62.0% vs -3.5%). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (45.0% CAGR vs -4.7%).
Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
CLOV vs OGN — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $749.2M | $1.5B |
| Net Profit | $27.3M | $146.0M |
| Gross Margin | — | 53.6% |
| Operating Margin | 3.6% | — |
| Net Margin | 3.6% | 10.0% |
| Revenue YoY | 62.0% | -3.5% |
| Net Profit YoY | — | 67.8% |
| EPS (diluted) | $0.05 | $0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $749.2M | $1.5B | ||
| Q4 25 | $487.7M | $1.5B | ||
| Q3 25 | $496.6M | $1.6B | ||
| Q2 25 | $477.6M | $1.6B | ||
| Q1 25 | $462.3M | $1.5B | ||
| Q4 24 | $337.0M | $1.6B | ||
| Q3 24 | $331.0M | $1.6B | ||
| Q2 24 | $356.3M | $1.6B |
| Q1 26 | $27.3M | $146.0M | ||
| Q4 25 | $-49.3M | $-205.0M | ||
| Q3 25 | $-24.4M | $160.0M | ||
| Q2 25 | $-10.6M | $145.0M | ||
| Q1 25 | $-1.3M | $87.0M | ||
| Q4 24 | $-22.1M | $109.0M | ||
| Q3 24 | $-9.2M | $359.0M | ||
| Q2 24 | $7.4M | $195.0M |
| Q1 26 | — | 53.6% | ||
| Q4 25 | — | 49.2% | ||
| Q3 25 | — | 53.5% | ||
| Q2 25 | — | 54.8% | ||
| Q1 25 | — | 55.6% | ||
| Q4 24 | — | 56.3% | ||
| Q3 24 | 24.5% | 58.3% | ||
| Q2 24 | 30.3% | 58.4% |
| Q1 26 | 3.6% | — | ||
| Q4 25 | -10.1% | -9.8% | ||
| Q3 25 | -4.9% | 15.2% | ||
| Q2 25 | -2.2% | 14.4% | ||
| Q1 25 | -0.3% | 6.7% | ||
| Q4 24 | -6.4% | 8.1% | ||
| Q3 24 | -2.7% | 13.1% | ||
| Q2 24 | 2.0% | 14.6% |
| Q1 26 | 3.6% | 10.0% | ||
| Q4 25 | -10.1% | -13.6% | ||
| Q3 25 | -4.9% | 10.0% | ||
| Q2 25 | -2.2% | 9.1% | ||
| Q1 25 | -0.3% | 5.8% | ||
| Q4 24 | -6.6% | 6.8% | ||
| Q3 24 | -2.8% | 22.7% | ||
| Q2 24 | 2.1% | 12.1% |
| Q1 26 | $0.05 | $0.55 | ||
| Q4 25 | — | $-0.78 | ||
| Q3 25 | — | $0.61 | ||
| Q2 25 | — | $0.56 | ||
| Q1 25 | — | $0.33 | ||
| Q4 24 | — | $0.42 | ||
| Q3 24 | — | $1.38 | ||
| Q2 24 | — | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.6M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $339.4M | — |
| Total Assets | $697.7M | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $177.6M | — | ||
| Q4 25 | $78.3M | $574.0M | ||
| Q3 25 | — | $672.0M | ||
| Q2 25 | — | $599.0M | ||
| Q1 25 | — | $547.0M | ||
| Q4 24 | $194.5M | $675.0M | ||
| Q3 24 | $288.0M | $763.0M | ||
| Q2 24 | $254.8M | $704.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $8.6B | ||
| Q3 25 | — | $8.8B | ||
| Q2 25 | — | $8.9B | ||
| Q1 25 | — | $9.0B | ||
| Q4 24 | — | $8.9B | ||
| Q3 24 | — | $8.7B | ||
| Q2 24 | — | $8.7B |
| Q1 26 | $339.4M | — | ||
| Q4 25 | $308.7M | $752.0M | ||
| Q3 25 | $340.9M | $906.0M | ||
| Q2 25 | $344.2M | $733.0M | ||
| Q1 25 | $336.1M | $542.0M | ||
| Q4 24 | $341.1M | $472.0M | ||
| Q3 24 | $342.2M | $493.0M | ||
| Q2 24 | $324.9M | $144.0M |
| Q1 26 | $697.7M | — | ||
| Q4 25 | $541.0M | $12.9B | ||
| Q3 25 | $559.7M | $13.6B | ||
| Q2 25 | $575.0M | $13.5B | ||
| Q1 25 | $583.7M | $13.2B | ||
| Q4 24 | $580.7M | $13.1B | ||
| Q3 24 | $653.0M | $12.8B | ||
| Q2 24 | $674.2M | $12.2B |
| Q1 26 | — | — | ||
| Q4 25 | — | 11.49× | ||
| Q3 25 | — | 9.74× | ||
| Q2 25 | — | 12.14× | ||
| Q1 25 | — | 16.52× | ||
| Q4 24 | — | 18.81× | ||
| Q3 24 | — | 17.75× | ||
| Q2 24 | — | 60.11× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLOV
Segment breakdown not available.
OGN
| Established Brands | $880.0M | 60% |
| Women’s Health | $389.0M | 27% |
| Biosimilars | $173.0M | 12% |
